Archives

  • 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2020-03
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • br associations but not causation Finally even

    2022-05-09

    
    associations, but not causation. Finally, even though statistically necessary, risk matchingusing propensityscore mayhave maskedtrue and relevant associations. Despite the performance of extensive analyses and the overall comprehensive nature of the NIS dataset employed, the precise factors underlying IHCA and survival to discharge, including cancer disease status, discordance in physician and patient perception of cancer severity and prognosis, patient-physician discussion of goals of care, and use of active or recent treatments could not be determined. Finally, even though we attempted to define a group of patients in the ICU setting, APR-DRG is only an administrative marker of severity and not a true marker of clinical sickness. Further elucidation of these interactions will require prospective studies, or retrospective analyses with greater clinical granularity.
    Conclusions
    Despite similar rates of in-hospital cardiac arrest and CPR use, cancer patients have lower survival to discharge than patients without cancer. This difference persists even after controlling for general prognosis and comorbidity status and appears to be associated with less aggressive use of post-resuscitation procedures, such as TTM, PCI and mechanical support. Additional research is needed to clarify the role of patient-physician perceptions of cancer prognosis and selective applications of post-resuscitation care.
    Conflict of interest
    All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr. Awan has received research funding from Innate Pharma, and Pharmacyclics, and provided consulting services to Gilead Sciences, Pharmacyclics, Inc, Janssen, Abbvie, Sunesis, AstraZeneca, Genentech, and Novartis Oncology, and served on the speakers bureau of Abbvie and AstraZeneca, and was supported in-part by NCI grant number R35-CA197734. Dr Woyach received research funding from Abbvie, Pharmacyclics, Janssen, Acerta, Loxo, Karyopharm, and Morphosys, and has consulted for Janssen and Pharmacyclics, and was supported by NCIK23-CA178183 and R01-CA197870. Dr. Oliveira receives honoraria from Abbott, Novartis and Abiomed none. Dr. Addison is supported by NCI grant number K12-CA133250. None of the authors above and all other authors have no relationships relevant to the contents of this Relebactam paper.
    Appendix A. Supplementary data
    1. Ofoma UR, Basnet S, Berger A, Kirchner HL, Girotra S, American Heart Association Get With the Guidelines – Resuscitation Investigators. Trends in survival after in-hospital cardiac arrest during nights and weekends. J Am Coll Cardiol 2018;71:402–11.
    2. Chan PS, Krein SL, Tang F, et al. Resuscitation practices associated with survival after in-hospital cardiac arrest: a Hydropathy plot nationwide survey. JAMA Cardiol 2016;1:189–97.
    3. Edelson DP, Litzinger B, Arora V, et al. Improving in-hospital cardiac arrest process and outcomes with performance debriefing. Arch Intern Med 2008;168:1063–9.
    continuous quality improvement: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 2015;132:S397–413.
    6. Neumar RW. Doubling cardiac arrest survival by 2020: achieving the American Heart Association impact goal. Circulation 2016;134:2037–9. 7. Monsieurs KG, Nolan JP, Bossaert LL, et al. European Resuscitation Council guidelines for resuscitation 2015: section 1. Executive summary. Resuscitation 2015;95:1–80.
    9. Wiczer TE, Levine LB, Brumbaugh J, et al. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. Blood Adv 2017;1:1739–48.
    10. Bruckel JT, Wong SL, Chan PS, Bradley SM, Nallamothu BK. Patterns of resuscitation care and survival after in-hospital cardiac arrest in patients with advanced cancer. J Oncol Pract 2017;13:e821–30.
    11. Nolan JP, Morley PT, Vanden Hoek TL, et al. Therapeutic hypothermia after cardiac arrest: an advisory statement by the advanced life support task force of the International Liaison Committee on Resuscitation. Circulation 2003;108:118–21.
    13. De Bruin ML, van Hemel NM, Leufkens HGM, Hoes AW. Hospital discharge diagnoses of ventricular arrhythmias and cardiac arrest were useful for epidemiologic research. J Clin Epidemiol 2005;58:1325–9.
    14. Sean H, Leonard CE, Freeman CP, et al. Validation of diagnostic codes for outpatient-originating sudden cardiac death and ventricular arrhythmia in medicaid and medicare claims data. Pharmacoepidemiol Drug Saf 2010;19:555–62. 
    15. Tamariz L, Harkins T, Nair V. A systematic review of validated methods for identifying ventricular arrhythmias using administrative and claims data. Pharmacoepidemiol Drug Saf 2012;21:148–53.